Video Library
Explore videos featuring leading oncology physicians offering their expert insights on key topics related to TEVIMBRA, including clinical data from phase 3 trials, product design, dosing, and access.
Explore videos featuring leading oncology physicians offering their expert insights on key topics related to TEVIMBRA, including clinical data from phase 3 trials, product design, dosing, and access.
Dosing Flexibility with TEVIMBRA
Navigating Formulary Access to TEVIMBRA
Dr. Dani Castillo, MD, discusses the process for obtaining formulary approval for TEVIMBRA in her practice.
Overall Survival Data and NCCN Recommendations
Dr. Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the latest National Comprehensive Cancer Network guidelines in upper GI cancers and examines overall survival data for patients treated with TEVIMBRA + chemotherapy vs placebo + chemotherapy.
PD-L1 Testing (TAP/CPS)
Dr. Ronan J. Kelly, MD, MBA, explains TAP, the PD-L1 expression methodology used in the clinical trials of TEVIMBRA.
RATIONALE-305 OS Subgroup Analyses
Dr. Dani Castillo, MD, reviews subgroup analyses of overall survival, which included positive outcomes with TEVIMBRA + chemotherapy in patients with peritoneal metastases.2
RATIONALE-305 Study Design
Dr. Ronan J. Kelly, MD, MBA, reviews RATIONALE-305, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable or metastatic, HER2-negative GC or GEJC.
RATIONALE-306 Study Design
Dr. Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, reviews RATIONALE-306, a phase 3 trial that evaluated efficacy and safety outcomes with TEVIMBRA + chemotherapy in patients with 1L, unresectable, advanced or metastatic ESCC.
TEVIMBRA Mechanism of Action
Dr. Ronan J. Kelly, MD, MBA, discusses what makes TEVIMBRA unique.
1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand 1.
References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Sonbol MB, Rha SY, Xu RH, et al. Abstract and poster presented at: ASCO Gastrointestinal Cancers Symposium; January 8-10, 2026. San Francisco, CA. Abstract 378, poster D9.